Apellis Pharmaceuticals, Inc. (APLS) 是一家上市公司 屬於 醫療保健 板塊，經營於 生物科技 產業. 公司總部位於 Waltham, MA, 美国. 現任CEO為 Cedric Francois.
APLS 擁有 IPO日期為 2017-11-09, 705 名全職員工, 在 NASDAQ Global Select, 市值為 $5.22B.
Apellis Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company focused on discovering, developing, and commercializing therapeutic compounds that inhibit the complement system to treat autoimmune and inflammatory diseases. The company's lead product, pegcetacoplan, is in Phase III clinical trials for geographic atrophy in age-related macular degeneration and paroxysmal nocturnal hemoglobinuria, with the approved product EMPAVELI addressing multiple rare hematologic, nephrologic, and neurologic indications. Apellis maintains a robust pipeline including APL-2006, a bispecific C3 and VEGF inhibitor, and APL-1030, a C3 inhibitor for neurodegenerative diseases, supported by strategic collaborations with Swedish Orphan Biovitrum AB and Beam Therapeutics. Founded in 2009 and headquartered in Waltham, Massachusetts, the company is advancing complement-inhibition science across multiple therapeutic areas with significant unmet medical needs.
